Skip to main navigation Skip to search Skip to main content

DQB1 06:02 allele-specific expression varies by allelic dosage, not narcolepsy status

  • Karin Weiner Lachmi
  • , Ling Lin
  • , Birgitte Rahbek Kornum
  • , Tom Rico
  • , Betty Lo
  • , Adi Aran
  • , Emmanuel Mignot*
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

The association of narcolepsy-cataplexy, a sleep disorder caused by the loss of hypocretin/orexin neurons in the hypothalamus, with DQA1*01:02-DQB1*06:02 is one of the tightest known single-allele human leukocyte antigen (HLA) associations. In this study, we explored genome-wide expression in peripheral white blood cells of 50 narcolepsy versus 47 controls (half of whom were DQB1*06:02 positive) and observed the largest differences between the groups in the signal from HLA probes. Further studies of HLA-DQ expression (mRNA and protein in a subset) in 125 controls and 147 narcolepsy cases did not reveal any difference, a result we explain by the lack of proper control of allelic diversity in Affymetrix HLA probes. Rather, a clear effect of DQB1*06:02 allelic dosage on DQB1*06:02 mRNA levels (1.65-fold) and protein (1.59-fold) could be demonstrated independent of disease status. These results indicate that allelic dosage is transmitted into changes in heterodimer availability, a phenomenon that may explain the increased risk for narcolepsy in DQB1*06:02 homozygotes versus heterozygotes.

Original languageEnglish
Pages (from-to)405-410
Number of pages6
JournalHuman Immunology
Volume73
Issue number4
DOIs
StatePublished - Apr 2012
Externally publishedYes

Keywords

  • DQB1*06:02
  • Gene expression
  • Human leukocyte antigen
  • Narcolepsy

Fingerprint

Dive into the research topics of 'DQB1 06:02 allele-specific expression varies by allelic dosage, not narcolepsy status'. Together they form a unique fingerprint.

Cite this